Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Visani

Showing results (51-60 of 103) with videos related to

Pageof 11
Sort By:
Haematologica|November 11, 2003
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcriptsGiovanni Martinelli, Emanuela Ottaviani, Silvia Buonamici, et al.
British Journal of Haematology|August 24, 2022
Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patientsAlessandro Isidori, Federica Loscocco, Giuseppe Visani, et al.
European Journal of Haematology|March 22, 2005
Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemiaAnna Mele, Giuliana Leopardi, Giovanni Sparaventi, et al.
Blood|January 10, 2002
Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable stateSilvia Buonamici, Emanuela Ottaviani, Nicoletta Testoni, et al.
Frontiers in Oncology|May 31, 2021
Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With NilotinibFederica Loscocco, Giuseppe Visani, Annamaria Ruzzo, et al.
Acta Haematologica|December 5, 2012
Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemiaRoberto Latagliata, Alessandro Isidori, Massimo Breccia, et al.
British Journal of Haematology|November 15, 2011
Interactions between killer immunoglobulin-like receptors and their human leucocyte antigen Class I ligands influence the outcome of unrelated haematopoietic stem cell transplantation for thalassaemia: a novel predictive algorithmRoberto Littera, Nicola Orrù, Giovanni Caocci, et al.
Mediterranean Journal of Hematology and Infectious Diseases|March 19, 2011
Outcome of allogeneic stem cell transplantation following reduced-intensity conditioninig regimen in patients with idiopathic myelofibrosis: the g.I.T.m.o. ExperienceFrancesca Patriarca, Andrea Bacigalupo, Alessandra Sperotto, et al.
The Oncologist|April 26, 2012
Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGAAttilio Olivieri, Guido Gini, Caterina Bocci, et al.
Haematologica|August 30, 2008
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)Francesca Patriarca, Andrea Bacigalupo, Alessandra Sperotto, et al.
Pageof 11

Showing results (51-60 of 103) with videos related to

Sort By:
Pageof 11
Haematologica|November 11, 2003
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcriptsGiovanni Martinelli, Emanuela Ottaviani, Silvia Buonamici, et al.
British Journal of Haematology|August 24, 2022
Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patientsAlessandro Isidori, Federica Loscocco, Giuseppe Visani, et al.
European Journal of Haematology|March 22, 2005
Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemiaAnna Mele, Giuliana Leopardi, Giovanni Sparaventi, et al.
Blood|January 10, 2002
Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable stateSilvia Buonamici, Emanuela Ottaviani, Nicoletta Testoni, et al.
Frontiers in Oncology|May 31, 2021
Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With NilotinibFederica Loscocco, Giuseppe Visani, Annamaria Ruzzo, et al.
Acta Haematologica|December 5, 2012
Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemiaRoberto Latagliata, Alessandro Isidori, Massimo Breccia, et al.
British Journal of Haematology|November 15, 2011
Interactions between killer immunoglobulin-like receptors and their human leucocyte antigen Class I ligands influence the outcome of unrelated haematopoietic stem cell transplantation for thalassaemia: a novel predictive algorithmRoberto Littera, Nicola Orrù, Giovanni Caocci, et al.
Mediterranean Journal of Hematology and Infectious Diseases|March 19, 2011
Outcome of allogeneic stem cell transplantation following reduced-intensity conditioninig regimen in patients with idiopathic myelofibrosis: the g.I.T.m.o. ExperienceFrancesca Patriarca, Andrea Bacigalupo, Alessandra Sperotto, et al.
The Oncologist|April 26, 2012
Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGAAttilio Olivieri, Guido Gini, Caterina Bocci, et al.
Haematologica|August 30, 2008
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)Francesca Patriarca, Andrea Bacigalupo, Alessandra Sperotto, et al.
Pageof 11